{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:19:07Z","timestamp":1786573147450,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Provincial Plans - Social Development Areas - Major Projects of Jiangxi Province","award":["20161ACG70012"],"award-info":[{"award-number":["20161ACG70012"]}]},{"name":"the \u201c5511\u201d Innovative Drivers for Talent Teams of Jiangxi Province","award":["20165BCB18018"],"award-info":[{"award-number":["20165BCB18018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10741-019-09790-5","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T08:06:12Z","timestamp":1556352372000},"page":"637-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"24","author":[{"given":"Pingping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,27]]},"reference":[{"key":"9790_CR1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jim\u00e9nez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O\u2019Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee (2018) Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137:e67\u2013e492","journal-title":"Circulation"},{"key":"9790_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137\u20131146","journal-title":"Heart"},{"key":"9790_CR3","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1067\/mhj.2002.129971","volume":"144","author":"JW Funder","year":"2002","unstructured":"Funder JW (2002) New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 144:S8\u2013S11","journal-title":"Am Heart J"},{"key":"9790_CR4","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ (2003) Eplerenone: cardiovascular protection. Circulation 107:2512\u20132518","journal-title":"Circulation"},{"key":"9790_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrneph.2009.228","volume":"6","author":"RW Schrier","year":"2010","unstructured":"Schrier RW (2010) Aldosterone \u2018escape\u2019 vs \u2018breakthrough\u2019. Nat Rev Nephrol 6:61","journal-title":"Nat Rev Nephrol"},{"key":"9790_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"key":"9790_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1011119003788","volume":"15","author":"B Pitt","year":"2001","unstructured":"Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15:79\u201387","journal-title":"Cardiovasc Drugs Ther"},{"key":"9790_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mce.2003.10.009","volume":"217","author":"B Pitt","year":"2004","unstructured":"Pitt B (2004) Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217:53\u201358","journal-title":"Mol Cell Endocrinol"},{"key":"9790_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/eurheartj\/16.suppl_N.107","volume":"16","author":"D Pitt","year":"1995","unstructured":"Pitt D (1995) ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 16:107\u2013110","journal-title":"Eur Heart J"},{"key":"9790_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors\/Task Force Members, Document Reviewers (2016) Document reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891\u2013975","journal-title":"Eur J Heart Fail"},{"key":"9790_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 23:628\u2013651","journal-title":"J Card Fail"},{"key":"9790_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the randomized Aldactone Evaluation Study. N Engl J Med 351:543\u2013551","journal-title":"N Engl J Med"},{"key":"9790_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62:1585\u20131593","journal-title":"J Am Coll Cardiol"},{"key":"9790_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1001\/jama.2009.1493","volume":"302","author":"NM Albert","year":"2009","unstructured":"Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC (2009) Use of aldosterone antagonists in heart failure. JAMA 302:1658\u20131665","journal-title":"JAMA"},{"key":"9790_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-P\u00e9rez S, Heckroth H, Nitsche A, Erg\u00fcden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P (2012) Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:1385\u20131403","journal-title":"ChemMedChem"},{"key":"9790_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, Eitner F, Albrecht-K\u00fcpper B, Sch\u00e4fer S (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64:69\u201378","journal-title":"J Cardiovasc Pharmacol"},{"key":"9790_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"P Kolkhof","year":"2012","unstructured":"Kolkhof P, Borden SA (2012) Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 350:310\u2013317","journal-title":"Mol Cell Endocrinol"},{"key":"9790_CR18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453\u20132463","journal-title":"Eur Heart J"},{"key":"9790_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37:2105\u20132114","journal-title":"Eur Heart J"},{"key":"9790_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000371497","volume":"40","author":"LM Ruilope","year":"2014","unstructured":"Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL (2014) Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol 40:572\u2013581","journal-title":"Am J Nephrol"},{"key":"9790_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314:884\u2013894","journal-title":"JAMA"},{"key":"9790_CR22","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105\u20133124","journal-title":"Stat Med"},{"key":"9790_CR23","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65\u2013W94","journal-title":"Ann Intern Med"},{"key":"9790_CR24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7:434\u2013455","journal-title":"J Comput Graph Stat"},{"key":"9790_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163\u2013171","journal-title":"J Clin Epidemiol"},{"key":"9790_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Angelika VDL (2002) Bayesian measures of model complexity and fit. J R Stat Soc 64:583\u2013639","journal-title":"J R Stat Soc"},{"key":"9790_CR27","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","volume":"60","author":"O Vardeny","year":"2012","unstructured":"Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60:2082\u20132089","journal-title":"J Am Coll Cardiol"},{"key":"9790_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"9790_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","volume":"11","author":"A Boccanelli","year":"2009","unstructured":"Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G (2009) Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 11:68\u201376","journal-title":"Eur J Heart Fail"},{"key":"9790_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/heart.85.4.e8","volume":"85","author":"C Berry","year":"2001","unstructured":"Berry C, McMurray JJV (2001) Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 85:8\u20139","journal-title":"Heart"},{"key":"9790_CR31","first-page":"527","volume":"104","author":"FA Masoudi","year":"2010","unstructured":"Masoudi FA, Gross CP (2010) Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States. Circulation 104:527\u2013549","journal-title":"Circulation"},{"key":"9790_CR32","doi-asserted-by":"publisher","first-page":"F559","DOI":"10.1152\/ajprenal.00320.2001","volume":"282","author":"JD Stockand","year":"2002","unstructured":"Stockand JD (2002) New ideas about aldosterone signaling in epithelia. Am J Physiol Renal Physiol 282:F559\u2013F576","journal-title":"Am J Physiol Renal Physiol"},{"key":"9790_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/joe.1.06017","volume":"186","author":"JM Connell","year":"2005","unstructured":"Connell JM, Davies E (2005) The new biology of aldosterone. J Endocrinol 186:1\u201320","journal-title":"J Endocrinol"},{"key":"9790_CR34","first-page":"772","volume":"33","author":"M Delbeck","year":"2012","unstructured":"Delbeck M, Kretschmer A, Kast R, Ba\u00a8rfacker L, Hartmann E, Schaefer S, Kolkhof P (2012) Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure. Eur Heart J 33:772\u2013773","journal-title":"Eur Heart J"},{"key":"9790_CR35","first-page":"978","volume":"33","author":"P Kolkhof","year":"2012","unstructured":"Kolkhof P, Kretschmer A, Baerfacker L, Hartmann E, Schaefer S (2012) Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist. Eur Heart J 33:978\u2013979","journal-title":"Eur Heart J"},{"key":"9790_CR36","first-page":"7","volume":"33","author":"B Albrecht-Ku\u00a8pper","year":"2012","unstructured":"Albrecht-Ku\u00a8pper B, Kretschmer A, Kast R, Baerfacker L, Schaefer S, Kolkhof P (2012) Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure. Eur Heart J 33:7","journal-title":"Eur Heart J"},{"key":"9790_CR37","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","volume":"80","author":"N Sato","year":"2016","unstructured":"Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T (2016) A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease. Circ J 80:1113\u20131122","journal-title":"Circ J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09790-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09790-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09790-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T10:26:34Z","timestamp":1721211994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09790-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,27]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9790"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09790-5","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,27]]},"assertion":[{"value":"27 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}